إسرائيل - العربية - Ministry of Health

abic ltd. - chloramphenicol 3 %; prednisolone 0.5 % - ointment - prednisolone - infected eczema, pruritic lesions, angular stomatitis, impetigo, external otitis and pyoderma and other skin infections caused by chloramphenicol susceptible organisms.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - clotrimazole 1 %; dexamethasone acetate 0.044 % - cream - dexamethasone - tevacutan is indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection.

إسرائيل - العربية - Ministry of Health

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - ciprofloxacin as hydrochloride 250 mg - tablets - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.